^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    simmitinib (SYHA1817)

    i
    Other names: SYHA1817, SOMCL-15-290
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    FGFR inhibitor, VEGFR-2 inhibitor, CSF-1R inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Study of Simmitinib Plus SG001 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=168, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
    New P1/2 trial • Metastases
    |
    simmitinib (SYHA1817)
    almost2years
    A Phase I Trial of Simmitinib in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Mar 2023 | Trial primary completion date: Oct 2021 --> Jan 2023
    Enrollment open • Trial completion date • Trial primary completion date
    |
    VEGFA (Vascular endothelial growth factor A)
    |
    simmitinib (SYHA1817)
    almost2years
    Development and validation of a high performance liquid chromatography-MS/MS method for determination of SOMCL-15-290 in a first-in-human study. (PubMed, Bioanalysis)
    Quantification of SOMCL-15-290 was operated on an Xevo-TQS triple quadrupole tandem mass spectrometer in electrospray ionization positive mode. Results & The validated determination method of SOMCL-15-290 has proved feasible and was successfully utilized in the first-in-human study of SOMCL-15-290 in advanced solid tumor patients.
    P1 data • Journal
    |
    KDR (Kinase insert domain receptor) • CSF1R (Colony stimulating factor 1 receptor)
    |
    simmitinib (SYHA1817)